MDGL Q4 2019 Earnings — Madrigal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

MDGLMadrigal Pharmaceuticals, Inc.

$10B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$30M

Net Income

-$28M

EPS (Diluted)

$-1.80

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$442M

Total Liabilities

$25M

Stockholders' Equity

$417M

Cash & Equivalents

$47M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$25,000	+100.0%
Operating Income	-$30M	-$14M	-107.2%
Net Income	-$28M	-$11M	-141.7%